Wedbush Reaffirms Outperform Rating for Immunome (NASDAQ:IMNM)
Immunome (NASDAQ:IMNM – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report issued on Thursday,Benzinga reports. They presently have a $33.00 target price on the stock. Wedbush’s target price suggests a potential upside of 303.42% from the company’s previous close. A number of other research firms have […]
Immunome (NASDAQ:IMNM – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report issued on Thursday,Benzinga reports. They presently have a $33.00 target price on the stock. Wedbush’s target price suggests a potential upside of 303.42% from the company’s previous close. A number of other research firms have […]
